Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.

Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, McKenna KM, Ho PY, Cheng RZ, Chen JY, Barkal LJ, Ring AM, Weissman IL, Maute RL.

Nat Immunol. 2018 Jan;19(1):76-84. doi: 10.1038/s41590-017-0004-z. Epub 2017 Nov 27.

2.

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.

Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL.

Nature. 2017 May 25;545(7655):495-499. doi: 10.1038/nature22396. Epub 2017 May 17.

3.

Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.

Mayer AT, Natarajan A, Gordon SR, Maute RL, McCracken MN, Ring AM, Weissman IL, Gambhir SS.

J Nucl Med. 2017 Apr;58(4):538-546. doi: 10.2967/jnumed.116.177659. Epub 2016 Dec 15.

4.

Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.

Pascolutti R, Sun X, Kao J, Maute RL, Ring AM, Bowman GR, Kruse AC.

Structure. 2016 Oct 4;24(10):1719-1728. doi: 10.1016/j.str.2016.06.026. Epub 2016 Sep 8.

5.

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, Guerston H, Barkal A, Trapani F, George J, Poirier JT, Gardner EE, Miles LA, de Stanchina E, Lofgren SM, Vogel H, Winslow MM, Dive C, Thomas RK, Rudin CM, van de Rijn M, Majeti R, Garcia KC, Weissman IL, Sage J.

J Clin Invest. 2016 Jul 1;126(7):2610-20. doi: 10.1172/JCI81603. Epub 2016 Jun 13.

6.

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.

Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG, Kimura R, Tsai JM, Manglik A, Kruse AC, Gambhir SS, Weissman IL, Ring AM.

Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6506-14. doi: 10.1073/pnas.1519623112. Epub 2015 Nov 10.

7.

MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas.

Schneider C, Setty M, Holmes AB, Maute RL, Leslie CS, Mussolin L, Rosolen A, Dalla-Favera R, Basso K.

Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8185-90. doi: 10.1073/pnas.1322466111. Epub 2014 May 19.

8.

RNAs with multiple personalities.

Maute RL, Dalla-Favera R, Basso K.

Wiley Interdiscip Rev RNA. 2014 Jan-Feb;5(1):1-13. doi: 10.1002/wrna.1193. Epub 2013 Aug 20. Review.

PMID:
24039180
9.

A mutation in mouse Pak1ip1 causes orofacial clefting while human PAK1IP1 maps to 6p24 translocation breaking points associated with orofacial clefting.

Ross AP, Mansilla MA, Choe Y, Helminski S, Sturm R, Maute RL, May SR, Hozyasz KK, Wójcicki P, Mostowska A, Davidson B, Adamopoulos IE, Pleasure SJ, Murray JC, Zarbalis KS.

PLoS One. 2013 Jul 25;8(7):e69333. doi: 10.1371/journal.pone.0069333. Print 2013.

10.

tRNA-derived microRNA modulates proliferation and the DNA damage response and is down-regulated in B cell lymphoma.

Maute RL, Schneider C, Sumazin P, Holmes A, Califano A, Basso K, Dalla-Favera R.

Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1404-9. doi: 10.1073/pnas.1206761110. Epub 2013 Jan 7.

11.

Identification of the human mature B cell miRNome.

Basso K, Sumazin P, Morozov P, Schneider C, Maute RL, Kitagawa Y, Mandelbaum J, Haddad J Jr, Chen CZ, Califano A, Dalla-Favera R.

Immunity. 2009 May;30(5):744-52. doi: 10.1016/j.immuni.2009.03.017. Epub 2009 May 14.

12.

Spectrophotometric determination of methanol in lactic acid through the hydrolysis and vacuum stripping of methyl lactate.

Maute RL, Benson RH, Martelli E.

Anal Chem. 1968 Jul;40(8):1380-1381. doi: 10.1021/ac60264a060. No abstract available.

PMID:
28190344

Supplemental Content

Loading ...
Support Center